![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) with Preexisting Resistance and Viral Blips
|
|
|
IAS 2021 July 18-22
Kristen Andreatta, Silvia Chang, Madalyn Delaney, Madeleine Willkom, Ross Martin, Sean Collins, Hal Martin, Kirsten L. White
Gilead Sciences, Inc., Foster City, California, USA
![0720211](../images/072021/072021-6/0720211.gif)
![0720212](../images/072021/072021-6/0720212.gif)
![0720213](../images/072021/072021-6/0720213.gif)
![0720214](../images/072021/072021-6/0720214.gif)
![0720215](../images/072021/072021-6/0720215.gif)
![0720216](../images/072021/072021-6/0720216.gif)
![0720217](../images/072021/072021-6/0720217.gif)
![0720218](../images/072021/072021-6/0720218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|